Literature DB >> 2683835

A double-blind comparison between a new multidose powder inhaler (Turbuhaler) and metered dose inhaler in children with asthma.

C Hultquist1, H Ahlström, N I Kjellman, L A Malmqvist, E Svenonius, S Melin.   

Abstract

Turbuhaler is a ready-loaded multiple dose inhaler which does not require co-ordination between release of dose and inhalation. 57 children with asthma participated in this clinical trial to compare the clinical effect and acceptance of terbutaline sulphate via Turbuhaler with that of metered dose inhaler (MDI). The trial consisted of two parts. In the first part of the study, which made use of a double-blind cross-over design, the clinical effect and number of treatment occasions with Turbuhaler were compared with those of MDI. In the second part, which was open, all patients were treated with Turbuhaler for 2 weeks. At the end of this period the patients were asked to make a subjective assessment of effect and to state their preference. There was no difference in clinical effect and number of treatment occasions between Turbuhaler and MDI. A majority of the patients thought Turbuhaler had the best effect and was easy to use.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2683835     DOI: 10.1111/j.1398-9995.1989.tb04184.x

Source DB:  PubMed          Journal:  Allergy        ISSN: 0105-4538            Impact factor:   13.146


  8 in total

1.  Systematic review of clinical effectiveness of pressurised metered dose inhalers versus other hand held inhaler devices for delivering beta (2 )agonists bronchodilators in asthma.

Authors:  F S Ram; J Wright; D Brocklebank; J E White
Journal:  BMJ       Date:  2001-10-20

Review 2.  Antiasthma drug delivery. What is on the horizon?

Authors:  J C Virchow; C Kroegel; H Matthys
Journal:  Clin Pharmacokinet       Date:  1994-08       Impact factor: 6.447

Review 3.  Review of therapeutically equivalent alternatives to short acting beta(2) adrenoceptor agonists delivered via chlorofluorocarbon-containing inhalers.

Authors:  D A Hughes; A Woodcock; T Walley
Journal:  Thorax       Date:  1999-12       Impact factor: 9.139

Review 4.  Budesonide. An appraisal of the basis of its pharmacoeconomic and quality-of-life benefits in asthma.

Authors:  R Davis; D McTavish
Journal:  Pharmacoeconomics       Date:  1995-05       Impact factor: 4.981

Review 5.  Inhalation devices for asthma. Choosing the right one could make all the difference.

Authors:  P M Fong; D E Sinclair
Journal:  Can Fam Physician       Date:  1993-11       Impact factor: 3.275

6.  Importance of the inhalation device on the effect of budesonide.

Authors:  L Agertoft; S Pedersen
Journal:  Arch Dis Child       Date:  1993-07       Impact factor: 3.791

Review 7.  Pharmacological factors that influence the choice of inhaled corticosteroids.

Authors:  S Edsbäcker
Journal:  Drugs       Date:  1999       Impact factor: 9.546

8.  Comparative efficacy of terbutaline sulphate delivered by Turbuhaler dry powder inhaler or pressurised metered dose inhaler with Nebuhaler spacer in children during an acute asthmatic episode.

Authors:  S Drblik; G Lapierre; R Thivierge; J Turgeon; P Gaudreault; B Cummins-McManus; I Verdy; J Haddon; J Lee; S Spier
Journal:  Arch Dis Child       Date:  2003-04       Impact factor: 3.791

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.